• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

T 细胞表面 PD-1 的表达受 HNRNPK 通过外显子 3 上的外显子剪接沉默子抑制。

Surface PD-1 expression in T cells is suppressed by HNRNPK through an exonic splicing silencer on exon 3.

机构信息

State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of Stomatology, School & Hospital of Stomatology, Wuhan University, Wuhan, 430079, China.

RNA Institute, Wuhan University, Wuhan, 430072, China.

出版信息

Inflamm Res. 2024 Jul;73(7):1123-1135. doi: 10.1007/s00011-024-01887-4. Epub 2024 May 2.

DOI:10.1007/s00011-024-01887-4
PMID:38698180
Abstract

OBJECTIVE

Immunotherapy targeting programmed cell death 1 (PDCD1 or PD-1) and its ligands has shown remarkable promise and the regulation mechanism of PD-1 expression has received arising attention in recent years. PDCD1 exon 3 encodes the transmembrane domain and the deletion of exon 3 produces a soluble protein isoform of PD-1 (sPD-1), which can enhance immune response by competing with full-length PD-1 protein (flPD-1 or surface PD-1) on T cell surface. However, the mechanism of PDCD1 exon 3 skipping is unclear.

METHODS

The online SpliceAid program and minigene expression system were used to analyze potential splicing factors involved in the splicing event of PDCD1 exon 3. The potential binding motifs of heterogeneous nuclear ribonucleoprotein K (HNRNPK) on exon 3 predicted by SpliceAid were mutated by site-directed mutagenesis technology, which were further verified by pulldown assay. Antisense oligonucleotides (ASOs) targeting the exonic splicing silencer (ESS) on PDCD1 exon 3 were synthesized and screened to suppress the skipping of exon 3. The alternative splicing of PDCD1 exon 3 was analyzed by semiquantitative reverse transcription PCR. Western blot and flow cytometry were performed to detect the surface PD-1 expression in T cells.

RESULTS

HNRNPK was screened as a key splicing factor that promoted PDCD1 exon 3 skipping, causing a decrease in flPD-1 expression on T cell membrane and an increase in sPD-1 expression. Mechanically, a key ESS has been identified on exon 3 and can be bound by HNRNPK protein to promote exon 3 skipping. Blocking the interaction between ESS and HNRNPK with an ASO significantly reduced exon 3 skipping. Importantly, HNRNPK can promote exon 3 skipping of mouse Pdcd1 gene as well.

CONCLUSIONS

Our study revealed a novel evolutionarily conserved regulatory mechanism of PD-1 expression. The splicing factor HNRNPK markedly promoted PDCD1 exon 3 skipping by binding to the ESS on PDCD1 exon 3, resulting in decreased expression of flPD-1 and increased expression of sPD-1 in T cells.

摘要

目的

针对程序性细胞死亡蛋白 1(PDCD1 或 PD-1)及其配体的免疫疗法显示出了显著的前景,近年来,PD-1 表达的调控机制受到了越来越多的关注。PDCD1 外显子 3 编码跨膜结构域,外显子 3 的缺失会产生 PD-1 的可溶性蛋白同工型(sPD-1),它可以通过与 T 细胞膜表面全长 PD-1 蛋白(flPD-1 或表面 PD-1)竞争来增强免疫反应。然而,PDCD1 外显子 3 跳跃的机制尚不清楚。

方法

使用在线 SpliceAid 程序和小基因表达系统分析参与 PDCD1 外显子 3 剪接事件的潜在剪接因子。通过定点突变技术对 SpliceAid 预测的异质核核糖核蛋白 K(HNRNPK)在外显子 3 上的潜在结合基序进行突变,并通过下拉实验进一步验证。针对 PDCD1 外显子 3 exon 剪接沉默子(ESS)的反义寡核苷酸(ASO)被合成并筛选,以抑制外显子 3 的跳跃。通过半定量逆转录 PCR 分析 PDCD1 外显子 3 的选择性剪接。通过 Western blot 和流式细胞术检测 T 细胞表面 PD-1 的表达。

结果

筛选出 HNRNPK 作为关键剪接因子,促进 PDCD1 外显子 3 跳跃,导致 T 细胞膜上 flPD-1 表达减少,sPD-1 表达增加。从机制上讲,在外显子 3 上鉴定出一个关键的 ESS,它可以与 HNRNPK 蛋白结合,促进外显子 3 跳跃。用 ASO 阻断 ESS 与 HNRNPK 之间的相互作用,显著减少外显子 3 跳跃。重要的是,HNRNPK 也可以促进小鼠 Pdcd1 基因的外显子 3 跳跃。

结论

本研究揭示了 PD-1 表达的一种新的进化保守调控机制。剪接因子 HNRNPK 通过与 PDCD1 外显子 3 上的 ESS 结合,显著促进 PDCD1 外显子 3 跳跃,导致 T 细胞中 flPD-1 表达减少,sPD-1 表达增加。

相似文献

1
Surface PD-1 expression in T cells is suppressed by HNRNPK through an exonic splicing silencer on exon 3.T 细胞表面 PD-1 的表达受 HNRNPK 通过外显子 3 上的外显子剪接沉默子抑制。
Inflamm Res. 2024 Jul;73(7):1123-1135. doi: 10.1007/s00011-024-01887-4. Epub 2024 May 2.
2
An anti-PD-1 antisense oligonucleotide promotes the expression of soluble PD-1 by blocking the interaction between SRSF3 and an exonic splicing enhancer of PD-1 exon 3.一种抗 PD-1 反义寡核苷酸通过阻断 SRSF3 与 PD-1 外显子 3 外显子剪接增强子之间的相互作用,促进可溶性 PD-1 的表达。
Int Immunopharmacol. 2024 Jan 5;126:111280. doi: 10.1016/j.intimp.2023.111280. Epub 2023 Dec 4.
3
Modulation of exon 3 splicing.外显子 3 剪接的调节。
RNA Biol. 2019 Dec;16(12):1794-1805. doi: 10.1080/15476286.2019.1659080. Epub 2019 Aug 28.
4
MRPL33 and its splicing regulator hnRNPK are required for mitochondria function and implicated in tumor progression.MRPL33 及其剪接调节因子 hnRNPK 对于线粒体功能是必需的,并与肿瘤进展有关。
Oncogene. 2018 Jan 4;37(1):86-94. doi: 10.1038/onc.2017.314. Epub 2017 Sep 4.
5
Epigenetic Control of Cancer Cell Proliferation and Cell Cycle Progression by HNRNPK via Promoting Exon 4 Inclusion of Histone Code Reader SPIN1.HNRNPK通过促进组蛋白编码阅读器SPIN1外显子4的包含对癌细胞增殖和细胞周期进程进行表观遗传控制。
J Mol Biol. 2023 Mar 15;435(6):167993. doi: 10.1016/j.jmb.2023.167993. Epub 2023 Feb 2.
6
Regulation of a strong F9 cryptic 5'ss by intrinsic elements and by combination of tailored U1snRNAs with antisense oligonucleotides.通过内在元件以及定制的U1snRNAs与反义寡核苷酸的组合对强F9隐蔽5'剪接位点进行调控。
Hum Mol Genet. 2015 Sep 1;24(17):4809-16. doi: 10.1093/hmg/ddv205. Epub 2015 Jun 10.
7
Muscle-specific exonic splicing silencer for exon exclusion in human ATP synthase gamma-subunit pre-mRNA.用于人类ATP合酶γ亚基前体mRNA中外显子排除的肌肉特异性外显子剪接沉默子。
J Biol Chem. 2002 Mar 1;277(9):6974-84. doi: 10.1074/jbc.M110138200. Epub 2001 Dec 13.
8
An intronic polypyrimidine-rich element downstream of the donor site modulates cystic fibrosis transmembrane conductance regulator exon 9 alternative splicing.供体位点下游富含嘧啶的内含子元件调节囊性纤维化跨膜传导调节因子外显子9的可变剪接。
J Biol Chem. 2004 Apr 23;279(17):16980-8. doi: 10.1074/jbc.M313439200. Epub 2004 Feb 13.
9
Reversing T Cell Exhaustion by Converting Membrane PD-1 to Its Soluble form in Jurkat Cells; Applying The CRISPR/Cas9 Exon Skipping Strategy.通过将膜结合型程序性死亡受体-1(PD-1)转化为其可溶性形式逆转Jurkat细胞中的T细胞耗竭;应用CRISPR/Cas9外显子跳跃策略
Cell J. 2023 Sep 9;25(9):633-644. doi: 10.22074/cellj.2023.1999548.1269.
10
HnRNP C, YB-1 and hnRNP L coordinately enhance skipping of human MUSK exon 10 to generate a Wnt-insensitive MuSK isoform.异质性核糖核蛋白C、YB-1和异质性核糖核蛋白L协同增强人肌肉特异性激酶(MUSK)外显子10的跳跃,以产生一种对Wnt不敏感的MUSK异构体。
Sci Rep. 2014 Oct 30;4:6841. doi: 10.1038/srep06841.

本文引用的文献

1
The role of PD-1 signaling in health and immune-related diseases.PD-1 信号通路在健康和免疫相关疾病中的作用。
Front Immunol. 2023 May 16;14:1163633. doi: 10.3389/fimmu.2023.1163633. eCollection 2023.
2
SRSF3-Mediated Ki67 Exon 7-Inclusion Promotes Head and Neck Squamous Cell Carcinoma Progression via Repressing AKR1C2.SRSF3 介导的 Ki67 外显子 7 剪接体的包含促进头颈部鳞状细胞癌的进展,通过抑制 AKR1C2。
Int J Mol Sci. 2023 Feb 15;24(4):3872. doi: 10.3390/ijms24043872.
3
Epigenetic Control of Cancer Cell Proliferation and Cell Cycle Progression by HNRNPK via Promoting Exon 4 Inclusion of Histone Code Reader SPIN1.
HNRNPK通过促进组蛋白编码阅读器SPIN1外显子4的包含对癌细胞增殖和细胞周期进程进行表观遗传控制。
J Mol Biol. 2023 Mar 15;435(6):167993. doi: 10.1016/j.jmb.2023.167993. Epub 2023 Feb 2.
4
Effect of tacrolimus on soluble costimulatory molecules in patients with refractory myasthenia gravis.他克莫司对难治性重症肌无力患者可溶性共刺激分子的影响。
J Neuroimmunol. 2022 Nov 15;372:577955. doi: 10.1016/j.jneuroim.2022.577955. Epub 2022 Aug 27.
5
Galectin-3 Decreases 4-1BBL Bioactivity by Crosslinking Soluble and Membrane Expressed 4-1BB.半乳糖凝集素-3 通过交联可溶性和膜表达的 4-1BB 降低 4-1BBL 的生物活性。
Front Immunol. 2022 Jun 24;13:915890. doi: 10.3389/fimmu.2022.915890. eCollection 2022.
6
Low-Threshold, Highly Stable Colloidal Quantum Dot Short-Wave Infrared Laser enabled by Suppression of Trap-Assisted Auger Recombination.通过抑制陷阱辅助俄歇复合实现的低阈值、高稳定性胶体量子点短波红外激光器
Adv Mater. 2022 Jan;34(3):e2107532. doi: 10.1002/adma.202107532. Epub 2021 Nov 18.
7
HnRNP K mislocalisation is a novel protein pathology of frontotemporal lobar degeneration and ageing and leads to cryptic splicing.hnRNP K 蛋白定位异常是额颞叶痴呆和衰老的一种新型蛋白质病理学改变,并导致剪接的隐匿性。
Acta Neuropathol. 2021 Oct;142(4):609-627. doi: 10.1007/s00401-021-02340-0. Epub 2021 Jul 18.
8
Antisense technology: an overview and prospectus.反义技术:概述与展望。
Nat Rev Drug Discov. 2021 Jun;20(6):427-453. doi: 10.1038/s41573-021-00162-z. Epub 2021 Mar 24.
9
Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy.可溶性 PD-1:癌症免疫治疗的预测、预后和治疗价值。
Front Immunol. 2020 Nov 19;11:587460. doi: 10.3389/fimmu.2020.587460. eCollection 2020.
10
The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors.免疫检查点抑制剂引起的免疫相关不良事件的相关生物标志物。
J Exp Clin Cancer Res. 2020 Dec 14;39(1):284. doi: 10.1186/s13046-020-01749-x.